This suggests a novel mechanism of chemoresistance toward combination therapies involving TOP2 poisons/inhibitors and strongly argues for HMGA2 expression profiling to aid therapy decision making, in particular in AML patients. This evidence concerns the gene TOP2A and acute myeloid leukemia.